Renier Brentjens, a CAR T-cell pioneer, views armored CAR T-cells as a promising avenue for treating solid tumors and ...

Researchers from the City of Hope and Memorial Sloan Kettering (MSK) Cancer Center, US, have developed a tool named ...

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

Cancer Center have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient's likely response ...

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science of addressing critical issues with CAR T cell therapy in patients with ...

A new article outlines a new tool that measures blood inflammation as a marker for poor CAR T therapy outcomes.

Researchers with City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United ...

Discover Nkarta's groundbreaking cell therapy advancements, robust financials, and investment potential. Click here to read ...

A review of the side effects of CAR T-cell therapy, including CRS, ICANS, tumor lysis syndrome, and late-onset toxicities, and management strategies.

A multi-institutional team led by The University of Osaka developed a chimeric antigen receptor (CAR) T cell-based strategy ...

A study conducted by Prof. Thai-Yen Ling at National Taiwan University underscores the potential of small extracellular ...